Aeon Biopharma Inc

This is a standard, catch‑all proposal that authorizes the meeting to consider and act on any additional matters properly presented at the Annual Meeting or any adjournment thereof. It does not itself request approval of a specific corporate action but instead preserves procedural flexibility to address unforeseen or late-arising items, including routine ministerial matters, ad hoc corporate actions, or matters raised from the floor. The proxy statement explicitly states that at the date of filing the Company knows of no other matters to be presented, and further makes clear that the Named Proxies will have discretion to vote on any such matters for stockholders who have submitted proxies. From a governance perspective, this language is neutral and common; it enables management and the Board to respond to procedural contingencies without reconvening or delaying actions, which can reduce transactional friction. However, it also transfers decision-making discretion to the Named Proxies for any unannounced proposals, which can be important if dissident or activist proposals were to be introduced at the meeting, because shareholders who submit a proxy and do not give specific instructions effectively delegate their vote. For investors focused on governance, the material considerations are whether any substantive proposals could be introduced late, the extent to which proxies will follow the Board’s stated recommendations, and whether broker-delegated voting or proxy discretion rules might affect outcomes. The proxy also outlines the procedural deadlines and requirements for stockholder proposals and director nominations for the following year, which limits the practical window for meaningful shareholder-solicited business at the meeting. Overall, this item is procedural rather than substantive, presents low direct financial risk, and is unlikely to change shareholder rights absent a specific additional proposal being properly presented at the meeting.